Company Analysis
Sign in

Beam Therapeutics Inc. (BEAM)

Nasdaq: BEAM · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2018
Full chart Alerts Compare
Grade6.4
◀ Past 6.9● Present 6.6▶ Future 5.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$140M+120.0%
Net income-$80.0M+78.8%
Earnings per share$-0.81+82.3%
Operating cash flow-$345M+0.6%
Cash$302M+4.0%
Debtn/a
Shareholders’ equity$1.24B+68.8%
Shares, diluted98.9M+20.2%
Return on equity-6.5%
The recordfrom its filings
Filings in 202681
Newest filingNov 3 · 10-Q
Annual reportFeb 24, 2026
Quarterly reportNov 3, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$9.7M
Insider buys, 12 months$0.00
Patents granted12
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $147MNet income -$108MCash from operations -$389Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
19202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 3, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 16, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 2, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 25, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 4, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton BEAM · research, not advice